Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05236062 · ClinicalTrials.gov registry record · NA
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
A NA study of Graft Vs Host Disease and Chronic Graft Versus Host Disease, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT05236062: Recruiting NA study of Graft Vs Host Disease and Chronic Graft Versus Host Disease, sponsored by Dana-Farber Cancer Institute.
NCT05236062 is a NA study of Graft Vs Host Disease and Chronic Graft Versus Host Disease that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 36 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05236062, a NA study of Graft Vs Host Disease and Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is about determining if an aerobic and resistance exercise intervention is feasible in patients diagnosed with acute or chronic GVHD (Graft-Versus-Host Disease) after having an allogeneic stem cell transplant. The names of the study interventions involved in this study are: * Aerobic and resistance exercise (A+R) - Home-based aerobic and resistance exercise program * Attention control (AC) - Home-based stretching program
Primary Outcome
The primary outcome is feasibility and will be assessed by the proportion of patients completing the exercise intervention sessions with \>70% completion considered feasible.
Conditions Studied
Interventions
- BEHAVIORAL Exercise
- BEHAVIORAL Attention control
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2027-09-09 |
| Phase | NA |
What NCT05236062 shows while recruiting
NCT05236062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Exercise is the first listed.
NCT05236062 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05236062 about?
NCT05236062 is a clinical study titled "Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial". This study is about determining if an aerobic and resistance exercise intervention is feasible in patients diagnosed with acute or chronic GVHD (Graft-Versus-Host Disease) after having an allogeneic stem cell transplant. The names of the study interventions involved in this study are: * Aerobic an...
What is the current status of trial NCT05236062?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2022-04-14. Estimated completion is 2027-09-09.
What conditions does trial NCT05236062 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Chronic Graft Versus Host Disease, Acute-graft-versus-host Disease.
What interventions are being tested in trial NCT05236062?
The interventions under investigation include: Exercise (BEHAVIORAL), Attention control (BEHAVIORAL).
Who is sponsoring clinical trial NCT05236062?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05236062 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05236062's enrollment target sits among peer trials
36 25th of 36 higher than 12 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
RECRUITING · NA
-
Horizons Chronic Graft-Versus-Host-Disease Study
ACTIVE NOT RECRUITING · NA
-
Multidisciplinary Intervention In Chronic GVHD
ACTIVE NOT RECRUITING · NA
-
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
ACTIVE NOT RECRUITING · NA
-
Topical Vitamin D in Acute Graft Versus Host Disease of the Skin
COMPLETED · NA
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI